1Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College St, Toronto, ON M5S 3G9 Canada.
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College St, Toronto, ON M5S 3E5 Canada.
Commun Biol. 2019 Feb 1;2:48. doi: 10.1038/s42003-019-0296-7. eCollection 2019.
Substitution of serum and other clinically incompatible reagents is requisite for controlling product quality in a therapeutic cell manufacturing process. However, substitution with chemically defined compounds creates a complex, large-scale optimization problem due to the large number of possible factors and dose levels, making conventional process optimization methods ineffective. We present a framework for high-dimensional optimization of serum-free formulations for the expansion of human hematopoietic cells. Our model-free approach utilizes evolutionary computing principles to drive an experiment-based feedback control platform. We validate this method by optimizing serum-free formulations for first, TF-1 cells and second, primary T-cells. For each cell type, we successfully identify a set of serum-free formulations that support cell expansions similar to the serum-containing conditions commonly used to culture these cells, by experimentally testing less than 1 × 10 % of the total search space. We also demonstrate how this iterative search process can provide insights into factor interactions that contribute to supporting cell expansion.
在治疗性细胞制造过程中,替代血清和其他临床不相容的试剂是控制产品质量所必需的。然而,由于可能的因素和剂量水平众多,用化学定义的化合物替代会产生复杂的大规模优化问题,使得传统的工艺优化方法无效。我们提出了一种用于无血清配方优化的高维框架,以扩展人类造血细胞。我们的无模型方法利用进化计算原理来驱动基于实验的反馈控制平台。我们通过优化 TF-1 细胞和原代 T 细胞的无血清配方来验证这种方法。对于每种细胞类型,我们通过实验测试不到总搜索空间的 1%,成功地找到了一组支持与通常用于培养这些细胞的含血清条件相似的细胞扩增的无血清配方。我们还展示了这种迭代搜索过程如何提供有关支持细胞扩增的因素相互作用的见解。